Cytotoxic activities of novel formulation from Blue-O Medical Technology against pancreatic cancer cells

Pancreatic cancer is one of the most aggressive cancers with a very poor survival upon detection. Pancreatic ducts are channels responsible for secreting pancreatic juices into the small intestines to aid in digestion. Pancreatic duct cancers account for up to 80% of the total pancreatic cancers, and current treatment are not efficacious to control the progress of the disease. Preliminary results using new formulations from Blue-O medical show a specific killing of pancreatic cancer cells. In this project, we aim to determine the mechanisms of cell killing of the new formulation. Results of this study are necessary before progressing to the next stage of animal models.

Faculty Supervisor:

Dr. Horacio Bach

Student:

TBD

Partner:

Blue-O Technology Inc.

Discipline:

Medicine

Sector:

Life sciences

University:

University of British Columbia